The Temodar Combination Study

Toxicity of Treatment Also Monitored

Note: This study is closed
The study determined if temozolomide (Temodar) administered alone or in combination with thalidomide (Thalomid), isotretinion (Accutane) and/or celecoxib (Celebrex) was effective in the continued treatment of newly diagnosed glioblastoma multiforme patients who already had incurred radiation therapy. Also, the toxicity of this adjuvant treatment was studied.
The study included 176 patients who participated up to one year (or more if the doctor determined it necessary). The effectiveness is measured in terms of progression-free survival six months after the described treatment.
To read the Neuro-Oncology Journal Article, click here.
For specific information on the Temodar Combination study, please click here.